Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic re
- PDF / 846,126 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 26 Downloads / 182 Views
Journal of Translational Medicine Open Access
REVIEW
Human platelet lysate to substitute fetal bovine serum in hMSC expansion for translational applications: a systematic review M. Guiotto1,2* , W. Raffoul1, A. M. Hart2,3, M. O. Riehle2† and P. G. di Summa1†
Abstract Background: Foetal bovine serum (FBS), is the most commonly used culture medium additive for in vitro cultures, despite its undefined composition, its potential immunogenicity and possible prion/zoonotic transmission. For these reasons, significant efforts have been targeted at finding a substitute, such as serum free-media or human plateletlysates (hPL). Our aim is to critically appraise the state-of-art for hPL in the published literature, comparing its impact with FBS. Materials and methods: In June 2019 a systematic search of the entire Web of Science, Medline and PubMed database was performed with the following search terms: (mesenchymal stem cells) AND (fetal bovine serum OR fetal bovine calf ) AND (human platelet lysate). Excluded from this search were review articles that were published before 2005, manuscripts in which mesenchymal stem cells (MSCs) were not from human sources, and when the FBS controls were missing. Results: Based on our search algorithm, 56 papers were selected. A review of these papers indicated that hMSCs cultured with hPL showed a spindle-shaped elongated morphology, had higher proliferation indexes, similar cluster of differentiation (CD) markers and no significant variation in differentiation lineage (osteocyte, adipocyte, and chondrocyte) compared to those cultured with FBS. Main sources of primary hMSCs were either fat tissue or bone marrow; in a few studies cells isolated from alternative sources showed no relevant difference in their response. Conclusion: Despite the difference in medium choice and a lack of standardization of hPL manufacturing, the majority of publications support that hPL was at least as effective as FBS in promoting adhesion, survival and proliferation of hMSCs. We conclude that hPL should be considered a viable alternative to FBS in hMSCs culture—especially with a view for their clinical use. Keywords: Human platelet lysate, Foetal bovine serum, Mesenchymal stem cells, Adipose derived stem cells, Cell therapy
*Correspondence: [email protected]; [email protected] † M. O. Riehle and P. G. di Summa contributed equally and share the colast authorship 2 Centre for the Cellular Microenvironment, University of Glasgow, Glasgow, UK Full list of author information is available at the end of the article
The word “mesenchymal stem cells” or MSCs and “stromal cells” are here used as synonym despite the recent distinction between the tissue-specific (e.g. adipose, bone, cartilage, …) stem/progenitor cells and the old generic term mesenchymal stem cells [1].
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appr
Data Loading...
